Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conduction System of the Heart01:19

Conduction System of the Heart

4.4K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
4.4K
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

894
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
894
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
Electrophysiology of Normal Cardiac Rhythm01:19

Electrophysiology of Normal Cardiac Rhythm

2.0K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
2.0K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

769
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
769
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

885
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
885

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between vascular adhesion protein-1 and major adverse cardiovascular events in heart failure patients: a retrospective cohort analysis.

BMC cardiovascular disorders·2026
Same author

Correlation between vascular adhesion protein-1 and major adverse cardiovascular events in patients with atrial fibrillation.

Frontiers in cardiovascular medicine·2025
Same author

The association between coronary heart disease and the risk of developing colorectal polyps: insights from the UK Biobank.

Frontiers in oncology·2025
Same author

Identification and Validation of the Key Genes of Diabetic Vasculopathy: Evidence Based on Bioinformatics Analysis and Animal Study.

International journal of genomics·2025
Same author

Atrial Fibrillation Termination Success During Ablation: Insights From Pooled Clinical Studies.

Reviews in cardiovascular medicine·2025
Same author

Spleen-Heart Cross-Talk Through CD23-Mediated Signal Promotes Cardiac Remodeling.

Circulation research·2025

Related Experiment Video

Updated: Jun 2, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.6K

Lower Risk of New-Onset Atrial Fibrillation in Conduction System Pacing Compared With Right Ventricular Pacing.

Feng Li1, You Zhang1, Jian Huang1

  • 1Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Pacing and Clinical Electrophysiology : PACE
|January 15, 2025
PubMed
Summary

Conduction system pacing (CSP) significantly reduces new-onset atrial fibrillation (AF) compared to right ventricular pacing (RVP). Ventricular pacing burden of 20% or more may be key to CSP

Keywords:
His bundle pacingconduction system pacingleft bundle branch area pacingnew‐onset atrial fibrillationright ventricular pacing

More Related Videos

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.1K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

547

Related Experiment Videos

Last Updated: Jun 2, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.6K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.1K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

547

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Device Technology

Background:

  • Conduction system pacing (CSP) shows promise for improving patient outcomes over traditional right ventricular pacing (RVP).
  • The comparative impact of CSP versus RVP on the incidence of new-onset atrial fibrillation (AF) requires further elucidation.
  • Atrial fibrillation is a common complication following cardiac pacing procedures.

Purpose of the Study:

  • To systematically evaluate the risk of new-onset atrial fibrillation (AF) associated with conduction system pacing (CSP) compared to right ventricular pacing (RVP).
  • To identify potential factors influencing the risk of new-onset AF in patients undergoing CSP.

Main Methods:

  • A systematic literature search was conducted across four databases up to July 1, 2024.
  • Included studies compared the incidence or risk of new-onset AF between CSP and RVP groups.
  • Subgroup analyses and pooled risk assessments, considering ventricular pacing burden (Vp), were performed.

Main Results:

  • Six studies involving 1577 patients were analyzed.
  • The pooled incidence of new-onset AF was 0.09 for CSP and 0.27 for RVP.
  • CSP demonstrated a significantly lower pooled risk (RR 0.38) and adjusted risk (HR 0.32) of new-onset AF compared to RVP, particularly when Vp was ≥ 20%.

Conclusions:

  • Conduction system pacing is associated with a substantially reduced risk of new-onset atrial fibrillation when compared to right ventricular pacing.
  • A ventricular pacing burden of 20% or greater appears to be a critical factor in achieving the lower AF risk observed with CSP therapy.